Abstract: Disclosed is an electrode assembly, a battery, and a battery pack and a vehicle including the same. In the electrode assembly, a first electrode, a second electrode, and a separator interposed therebetween are wound based on a winding axis to define a core and an outer circumference. The first electrode includes a first active material portion coated with an active material layer and a first uncoated portion not coated with an active material layer along a winding direction. At least a part of the first uncoated portion is defined as an electrode tab by itself. The first uncoated portion includes a first portion adjacent to the core of the electrode assembly, a second portion adjacent to the outer circumference of the electrode assembly, and a third portion interposed between the first portion and the second portion. The first portion or the second portion has a smaller height than the third portion in the winding axis direction.

Abstract: Disclosed is an electrode assembly, a battery, and a battery pack and a vehicle including the same. In the electrode assembly, a first electrode, a second electrode, and a separator interposed therebetween are wound based on an axis to define a core and an outer circumference. The first electrode includes an uncoated portion at a long side end thereof and exposed out of the separator along a winding axis direction of the electrode assembly. A part of the uncoated portion is bent in a radial direction of the electrode assembly to form a bending surface region that includes overlapping layers of the uncoated portion, and in a partial region of the bending surface region, the number of stacked layers of the uncoated portion is 10 or more in the winding axis direction of the electrode assembly.

Abstract: Proposed is a CO2-reduction membrane electrode assembly (MEA), which is a novel MEA capable of changing a reaction condition to an alkaline condition from a problematic acidic condition unfavorable to reactions on a cathode side during catalytic reactions using a cation exchange membrane (CEM) as a separator. In addition, the MEA can reduce a hydrogen evolution reaction (HER), which is a side reaction. In addition, a method of manufacturing the MEA, and a CO2-reduction assembly including the MEA are also proposed.

Abstract: The present invention provides a cartilage regenerating composition including a fetal cartilage tissue-derived cell and an extracellular matrix derived from a fetal cartilage tissue, and a preparing method thereof. According to the present invention, the cartilage-regenerating composition may produce a three-dimensional tissue of a size suitable for use as a cartilage without a scaffold, may be easily transplantable regardless of the size and shape of the cartilage defect at the site of administration since it can be administered in the form of a gel, but has high application and adhesion, may exhibit a high binding ability to the host tissue, and may have a phenotype of mature cartilage tissue, thereby exhibiting an excellent cartilage regeneration effect.

Abstract: Proposed is a non-destructive osteochondral graft quality analysis method using a Micro-CT assay, rather than using an existing biochemical assay involving destructive pretreatment of osteochondral tissue samples. Since the GAG content of the osteochondral graft can be measured by the non-destructive method through the Micro-CT assay, the quality analysis of the osteochondral graft provided by a donor can be easily performed, and the therapeutic effect of the osteochondral transplantation can be improved by enabling the use of a graft with a GAG content of 70% or more.

Abstract: The present invention provides a composition comprising fetal cartilage tissue-derived cells and a fetal cartilage tissue-derived extracellular matrix as active ingredients for regenerating a growth plate. The composition for regenerating a growth plate can inhibit bone bridge formation in a growth plate injury region without a scaffold and differentiate to a growth plate cartilage tissue to effectively fill and regenerate the injured region therewith, whereby the regenerated growth plate tissue can recover growth ability. In addition, the composition is compatible with and safe to biological tissues and is characterized by high reproducibility and homogeneity.

Abstract: The present invention relates to a tissue adhesion agent having improved bio-tissue adhesiveness and bonding force by utilizing an adhesion-related gene. More specifically, a cartilage tissue adhesion composition prepared from fetal cartilage tissue-derived stem cells in which VCAN, CTGF, or EXT1 is inserted and expressed in an upregulated manner was found to show a remarkably superb adhesive force, compared to that prepared from fetal cartilage tissue-derived stem cells in which none of the genes are inserted. Accordingly, the cell composition in which the expression of VCAN, CTGF, or EXT1 is upregulated can be prepared into a tissue adhesion composition having improved bio-tissue adhesiveness and bonding force and VCAN, CTGF, or EXT1 can be provided as an additive composition for a tissue adhesion agent.

Abstract: The present invention provides a composition for regenerating nucleus pulposus and a composition for regenerating an intervertebral disc tissue, each comprising fetal cartilage tissue-derived cells and a fetal cartilage tissue-derived extracellular matrix as active ingredients, and a pharmaceutical composition comprising the composition as an active ingredient for preventing or treating a vertebral disease. Simulating features of the nucleus pulposus, such as compression and tensile strength, the composition for regenerating nucleus pulposus can be regenerated into a tissue similar thereto. The composition for regenerating nucleus pulposus can be implanted into an intervertebral disc to restore an injured intervertebral disc tissue. Hence, the pharmaceutical composition comprising same for preventing or treating a vertebral disease can be used as a basic therapeutic agent for a vertebral disease such as a herniated intervertebral disc.

Abstract: The present invention relates to a tissue fusion composition having tissue adhesion and differentiation characteristics, and a preparation method therefor. In the present invention, a tissue fusion composition in the form of a gel or sheet is prepared using stem cells and stem cell-derived extracellular matrix, and it has been confirmed that the composition adheres and binds superbly to biological tissues and can be differentiated into cartilage, bone, cornea, growth plate, and the like, and thus the composition can be used as an adhesive and a differentiation agent in regenerative therapy of damaged tissues or organs, therefore being ultimately and effectively usable as an agent for tissue fusion.

Abstract: Disclosed is a device for supporting hoop stress applied to a meniscus and preventing deviation of the meniscus, and the device for supporting hoop stress applied to a meniscus and preventing deviation of the meniscus may include an intermediate support member, one side extension member, and the other side extension member.

Abstract: Disclosed is a device for supporting hoop stress applied to a meniscus and preventing deviation of the meniscus, and the device for supporting hoop stress applied to a meniscus and preventing deviation of the meniscus may include an intermediate support member, one side extension member, and the other side extension member.

Abstract: The present invention provides a cartilage regenerating composition including a fetal cartilage tissue-derived cell and an extracellular matrix derived from a fetal cartilage tissue, and a preparing method thereof. According to the present invention, the cartilage-regenerating composition may produce a three-dimensional tissue of a size suitable for use as a cartilage without a scaffold, may be easily transplantable regardless of the size and shape of the cartilage defect at the site of administration since it can be administered in the form of a gel, but has high application and adhesion, may exhibit a high binding ability to the host tissue, and may have a phenotype of mature cartilage tissue, thereby exhibiting an excellent cartilage regeneration effect.

Abstract: The present invention relates to a method for preparing a biocompatible porcine cartilage-derived extracellular matrix membrane capable of adjusting an in-vovo degradation rate and a mechanical property, and a composition containing the porcine cartilage-derived extracellular matrix as an active ingredient, for preventing adhesion between tissues and/or organs. Despite its high biocompatibility as a natural material, cartilage tissue extracellular matrix has a short decomposition period and its mechanical property is weak, thereby restricting the application. Accordingly, a method of enhancing the mechanical property through physical or chemical treatment and radiation treatment has been developed. In the present invention, biomaterials of various formulations were produced by treating the porcine cartilage-derived extracellular matrix with physiochemical methods.

Abstract: The present invention provides a method for manufacturing a porous three-dimensional scaffold using animal tissue powder, comprising powdering an animal-derived tissue, decellularizing the animal-derived tissue before or after powdering it, or simultaneously with powdering it, and forming the decellularized animal-derived tissue powder into a porous three-dimensional scaffold by a particle leaching method.

Abstract: The present invention relates to a method for differentiating mesenchymal stem cells and culturing chondrocytes using a fibrin/HA(hyaluronate) composite whose biocompatibility and durability are enhanced, and a therapeutic composition containing the fibrin/HA composite, and more particularly, to a method for culturing chondrocytes and differentiating mesenchymal stem cells into chondrocytes using an alginate-coated fibrin/HA composite gel and a composition for treating a cartilage disease and a composition for treating a disc disease using a fibrin/HA composite scaffold containing a fibrin degradation inhibitor. According to the present invention, disadvantages of the traditional fibrin/HA composite being reduced in size and easily degraded in a short time period during culture were overcome, so that cells can be cultured in a more stable environment.

Abstract: The present invention relates to an ultrasound equipment for treating edema, and more particularly, to an ultrasound equipment to relieve symptoms of edema or repair cellular and tissue edemas by generating 20˜400 mW/cm2 of low intensity ultrasound and use thereof. The ultrasound equipment according to the present invention comprises a main control unit equipped with a control unit for ultrasound generation for generating a 20˜400 mW/cm2 of low intensity ultrasound, an ultrasound generator for generating ultrasound according to the operating state of the main control unit, an ultrasound vibrator vibrating according to the value of ultrasound data inputted from the ultrasound generator, and a probe for delivering ultrasound energy to a treatment site, and when the ultrasound equipment is used, it is possible to treat edema by increasing permeability in blood vessels.

Abstract: The present invention relates to a method for fabricating a cell-derived extracellular matrix scaffold, more particularly, to a method for fabricating a cell-derived extracellular matrix scaffold, the method comprising the steps of obtaining a chondrocyte/extracellular matrix (ECM) membrane from chondrocytes derived from animal cartilage, obtaining a pellet-type scaffold-free construct by culturing after centrifuging the obtained chondrocytes/extracellular matrix (ECM) membrane and freeze-drying the obtained pellet-type construct. The cell-derived ECM scaffold according to the invention is a porous scaffold fabricated using cartilage tissue engineered by culturing chondrocytes in an in vitro scaffold-free system, which is not reduced in size during the cultivation and thus useful for cartilage regeneration.

Abstract: The present invention relates to a method for preparing a cell-derived extracellular matrix membrane, more particularly, to a method for preparing a chondrocyte-derived ECM membrane, the method comprising the steps of forming a suitable thickness of ECM membrane by culturing chondrocytes derived from animal cartilage at a high concentration in vitro, and drying it after decellularization process. The cell-derived ECM membrane scaffold according to the present invention is composed of extracellular matrix secreted by chondrocytes so that the membrane has excellent biocompatibility as well as an immune-previlage effect specific to cartilage. Since the membrane also has a suitable compressive strength, it can be used to replace periosteum for cartilage regeneration or artificial collagen membrane and used as dura mater transplant material, a natural ECM membrane for treating skin loss, materials for cell transplantation and a growth factor delivery vehicle.

Abstract: The present invention relates to a method for preparing a cell-derived ECM scaffold to which chondrocytes or stem cells are attached, a method for cartilage regeneration by tissue engineering, which comprises using the cell-derived ECM scaffold, and a therapeutic composition for treating cartilage disorder, which contains the ECM scaffold as an effective component. More specifically, the present invention relates to a method for cartilage regeneration by tissue engineering, which comprises transplanting ECM scaffold, having chondrocytes or stem cells attached thereto, into cartilage defects, and a therapeutic composition for treating cartilage disorder, which contains the ECM scaffold, having chondrocytes or stem cells attached thereto, as an effective component.

Abstract: The present invention relates to an ultrasonic device for the treatment of arthritis, and more particularly, to an ultrasonic device for the treatment or prevention of degenerative arthritis, which is so structured that it generates ultrasonic waves with an intensity of 200-800 mW/cm2 and applies low-intensity ultrasonic energy of 100-400 mW/cm2 to cartilage cells deep in the skin's dermis. The inventive ultrasonic device comprises: a main control unit including an ultrasonic oscillation control unit allowing the generation of ultrasonic waves with a frequency of 0.1-5 MHz and low intensity of 200-800 mW/cm2; an ultrasonic generator for generating ultrasonic waves according to the control state of the main control unit; an ultrasonic vibrator that vibrates according to ultrasonic waves inputted from the ultrasonic generator; and a probe for transferring ultrasonic vibration to a joint to be treated.